About Alvogen Pharma (India) Private Limited
Data last updated:
Alvogen Pharma (India) Private Limited is a private limited company based in Bangalore, Karnataka, India, a subsidiary of Lotus Pharmaceuticals Co Ltd. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 13 April 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U74900KA2010PTC053204. Its GSTIN is 29AAICA5910C2ZW (Karnataka). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹55 Lakh and a paid-up capital of ₹51.18 Lakh. It is led by directors including Saral Thangam and Fjalar Kristjansson.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 147/F 8th Main 3rd Block Koramangala, Bangalore, Karnataka, India – 560034.
As per the financials filed for FY 2025, the company reported a revenue of ₹51.32 Cr, a decline of 6% compared to the previous year. For the same year it recorded a net profit of ₹7.79 Cr (net margin 15.2%) and EBITDA of ₹11.25 Cr (EBITDA margin 21.9%). Revenue has declined at a compounded annual rate (CAGR) of 54% over three years and 2% over five years.
The company has about 31 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 2 brands: Norwich Clinical Services and Lotus. The company has 7 deals on record (5 secondary share transfers, 2 funding rounds), with disclosed funding of ₹50.1 Lakh; the latest was in December 2020.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lotuspharm.com.
Company details
Contact details
Alvogen Pharma (India) Private Limited's registered office is in Bangalore, Karnataka. Its website is lotuspharm.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address147/F 8th Main 3rd Block Koramangala, Bangalore, Karnataka, India – 560034
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Alvogen Pharma (India) Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Alvogen Pharma (India) operates two associated brands: Norwich Clinical Services and Lotus. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Offers clinical research, biostudies, bioanalytical, pharmacovigilance, and training services worldwide. | norwichclinical.com | |
| Contract manufacturing for oral solid formulations is offered. | lotuspharm.com |
Business activity
The main business activity of Alvogen Pharma (India) is professional, scientific and technical. In detail, this covers other professional, scientific and technical activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities |
To see the full business activity and turnover split of Alvogen Pharma (India) Private Limited, buy the company report.
Financials of Alvogen Pharma (India) Private Limited
FY 2024 filings availableAlvogen Pharma (India) Private Limited reported revenue of ₹51.32 Cr (down 6% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 2% over five years, including a 6% fall in the latest year. EBITDA rose 17% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹11.25 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹7.79 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 21.9% | ||||
| Net Profit Margin | 15.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Alvogen Pharma (India) Private Limited, buy the company report.
Board of directors of Alvogen Pharma (India) Private Limited
Alvogen Pharma (India) has 4 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Divya Chandu Patel Also directs: Norwich Clinical Services Private Limited | Nominee Director | 01 May 2010 | 16 Years 5 Months | Current |
| Saral Thangam Also directs: Norwich Clinical Services Private Limited | Director | 20 Sep 2014 | 12 Years 1 Months | Current |
| Fjalar Kristjansson Also directs: Norwich Clinical Services Private Limited | Director | 13 Apr 2010 | 16 Years 6 Months | Current |
| Aditya Nagaraj Bellur Also directs: Norwich Clinical Services Private Limited, Ads Sensor Technik Private Limited, Smartbear Software India Private Limited and 1 more | Director | 13 Dec 2017 | 8 Years 10 Months | Current |
Auditor
Alvogen Pharma (India) Private Limited is audited by AMARNATH KAMATH & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| AMARNATH KAMATH & ASSOCIATES | FY 2023 | 000099S |
Shareholding
The shareholding of Alvogen Pharma (India) Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Alvogen Pharma (India) Private Limited, buy the company report.
Deals & funding
Alvogen Pharma (India) Private Limited has 7 deals on record (5 secondary share transfers, 2 funding rounds), with disclosed funding of ₹50.1 Lakh; the latest was in December 2020.
Deals on record (5 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2020 | Secondary share transfer | Undisclosed | Buyer: Lotus Pharmaceutical Co. Limited Seller: Alvogen Lux Holdings S A R L |
| Mar 2016 | Secondary share transfer | Undisclosed | Buyer: Lotus Pharmaceutical Co. Limited Seller: Alvogen Lux Holdings S A R L |
| Sep 2014 | Secondary share transfer | Undisclosed | Buyer: Alvogen Lux Holdings S A & Saral Thangam, Alvogen Lux Holdings S A R L Seller: 2 individuals |
| Mar 2012 | Secondary share transfer | Undisclosed | Buyer: Alvogen Lux Holdings S A R L Seller: Alvogen Pharma (India) Private Limited |
| Oct 2010 | Funding round | ₹27.3 Lakh | Investors: Alvogen Pharma (India) Private Limited , Alvogen Lux Holding |
To see the full deal history of Alvogen Pharma (India) Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Alvogen Pharma (India) Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Alvogen Pharma (India) Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Alvogen Pharma (India) has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Norwich Clinical Services Private Limited | U73100KA2009PTC051396 |
To see the full group structure of Alvogen Pharma (India) Private Limited, buy the company report.
Employees & EPFO
Alvogen Pharma (India) Private Limited has a workforce of 31 employees on its EPFO records as of Apr 09, 2024, across 1 active EPFO establishment.
GST
Alvogen Pharma (India) has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAICA5910C2ZW | Karnataka | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Alvogen Pharma (India) Private Limited, buy the company report.
Recent activity
Alvogen Pharma (India) Private Limited has 12 board changes on record since 2010: 4 appointments and 8 cessations. The latest: Petar Antonov ceased to be Director on 22 Dec 2022.
3 earlier events are in the company report.
News
Frequently asked questions
Alvogen Pharma (India) is an active private limited company based in Bangalore, Karnataka, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 13 April 2010 (16+ years old) and is registered under CIN U74900KA2010PTC053204.
Alvogen Pharma (India) has 4 current directors:
- Divya Chandu Patel - Nominee Director
- Saral Thangam - Director
- Fjalar Kristjansson - Director
- Aditya Nagaraj Bellur - Director
The latest financial statements of Alvogen Pharma (India) on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Alvogen Pharma (India) is 29AAICA5910C2ZW, registered in Karnataka. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Alvogen Pharma (India) is U74900KA2010PTC053204. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Alvogen Pharma (India) was incorporated on 13 April 2010, making it 16+ years old. It is registered with the Registrar of Companies, Bangalore.
Alvogen Pharma (India) has 7 deals on record (5 secondary share transfers, 2 funding rounds), with disclosed funding of ₹50.1 Lakh; the latest was in December 2020.
Petar Antonov ceased to be Director on 22 Dec 2022. Arni Hardarson ceased to be Nominee Director on 13 Mar 2019. Kevin Michael Bain ceased to be Nominee Director on 13 Mar 2019. Alvogen Pharma (India) has 12 board changes on record in total.
Alvogen Pharma (India) can be reached through the website lotuspharm.com. Its registered office is in Bangalore, Karnataka, India.
The registered office of Alvogen Pharma (India) is at 147F 8th Main 3rd Block Koramangala, Bangalore, Karnataka, India – 560034.